The drugmaker said Jan. 10 it discovered the lot contained a small amount of Enalapril Maleate, a drug substance used to manufacture another drug at the same facility. Enalapril Maleate is used to treat congestive heart failure and hypertension.
Chronic exposure to Enalapril Maleate increases the risk of birth defects in a developing fetus.
Taro has not received any reports of adverse events related to the recall.
Consumers with the affected lot should return the Lamotrigine tablets to their pharmacy. Retailers, pharmacies and distributors should stop distributing or dispensing the affected product and return it to Taro.
Read the full news release here.
More articles on pharmacy:
GAO report hits lax oversight of 340B drug program
Venture capitalist launches company to bring drug prices down
AMAG Pharmaceuticals replacing CEO, cutting 2 drugs
